Evidence map›Paper›PMID 41396967›Full record

ArticleEuropean surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes2026

Simultaneous Liver-Kidney Transplantation versus Liver Transplantation in End-Stage Liver Disease Patients with Kidney Dysfunction.

Sarah Bouari, Yitian Fang, Jacqueline van de Wetering, Vincent E de Meijer, Robert A Pol, Stefan P Berger, Wojciech G Polak, Hans Blokzijl, Aiko P J de Vries, Minneke J Coenraad and 6 more

Erratum issuedAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Sarah BouariErasmus MC Transplant Institute, Department of Surgery, Division of HPB and Transplant Surgery, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Yitian FangErasmus MC Transplant Institute, Department of Surgery, Division of HPB and Transplant Surgery, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Jacqueline van de WeteringErasmus MC Transplant Institute, Department of Internal Medicine, Section of Nephrology and Transplantation, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Vincent E de MeijerUMCG Comprehensive Transplant Center, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Robert A PolUMCG Comprehensive Transplant Center, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Stefan P BergerUMCG Comprehensive Transplant Center, Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Wojciech G PolakErasmus MC Transplant Institute, Department of Surgery, Division of HPB and Transplant Surgery, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Hans BlokzijlUMCG Comprehensive Transplant Center, Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Aiko P J de VriesLeiden Transplant Center, Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
Minneke J CoenraadDepartment of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
Hwai-Ding LamLeiden Transplant Center, Division of Transplantation, Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Dorottya K de VriesLeiden Transplant Center, Division of Transplantation, Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Robert J PorteErasmus MC Transplant Institute, Department of Surgery, Division of HPB and Transplant Surgery, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Caroline M den HoedErasmus MC Transplant Institute, Department of Gastroenterology and Hepatology, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Jan N M IJzermansErasmus MC Transplant Institute, Department of Surgery, Division of HPB and Transplant Surgery, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Robert C MinneeErasmus MC Transplant Institute, Department of Surgery, Division of HPB and Transplant Surgery, University Medical Center Rotterdam, Rotterdam, The Netherlands, r.minnee@erasmusmc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe role of simultaneous liver-kidney transplantation (SLKT) in end-stage liver disease patients with varying kidney dysfunction remains unclear. This study aims to compare clinical outcomes of SLKT recipients with those undergoing liver transplant alone (LTA) with comparable kidney dysfunction.

methodsThis retrospective cohort study included the SLKT cohort (n = 52) from the Dutch Organ Transplantation Registration and the LTA cohort (n = 829) from Erasmus Medical Center between 2000 and 2020. Patients were stratified by pretransplant renal function (chronic kidney disease [CKD] stages 3b-5) and pretransplant renal replacement therapy (RRT) status. Patient and graft survival, and renal function were compared across renal function strata.

resultsAcross CKD stages 3b and 4, there was no statistically significant difference in overall survival rates (p = 0.59 and p = 0.23, respectively). For patients with CKD stage 5 or RRT, patient survival rates at 1, 3, and 5 years posttransplant were significantly lower in the LTA group (60.3%, 51.7%, and 51.7%, respectively) compared to the SLKT group (90.0%, 90.0%, and 80.8%, p = 0.048). Death-censored liver graft survival rates at 1, 3, and 5 years were also significantly lower in the LTA group (59.8%, 49.9%, and 49.9%) versus SLKT group (86.4%, 86.4%, and 77.0%, p = 0.048). Cox proportional hazards model confirmed the association between SLKT and improved patient survival (HR 0.31, 95% CI: 0.10-0.98, p = 0.046).

conclusionFor patients with CKD stage 5 or those on pretransplant RRT, SLKT was associated with better survival outcomes compared to LTA. Primary etiology of liver disease and severity of kidney dysfunction should be considered when determining SLKT eligibility. Due to the limited group size, these findings should be interpreted with caution and further validated.

Indexed as

End Stage Liver DiseaseKidney TransplantationLiver TransplantationRenal Insufficiency, ChronicAdultFemaleGraft SurvivalHumansMaleMiddle AgedRetrospective StudiesAcute liver failureEnd-stage liver diseaseGraft survivalKidney transplantationLiver transplantation

Identifiers

PMID41396967
PMCPMC12845520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.